TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01158066

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: CT Cardiac
Description: the patient will undergo cardiac CT
Study: NCT01852630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefepime + Albumin
Description: cefepime + Albumin will be given for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem + Albumin
Description: Imipenem + Albumin will be given for 2 days.
Study: NCT01512706

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 160Eu/0.5ml in children (24 months-5 years old)
Description: inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 320Eu/0.5ml in children (24 months-5 years old)
Description: inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 640Eu/0.5ml in children (24 months-5 years old)
Description: inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1280Eu/0.5ml (without adjuvant) in children (24 months-5 years old)
Description: inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0Eu/0.5ml in children (24 months-5 years old)
Description: 0Eu/0.5ml placebo in 50 children aged 24 months-5 years old on day 0, 28
Study: NCT02086903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg
Description: The subjects administer Ticagrelor 90 mg as loading dose (LD) follow by 90 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Clopidogrel 600 mg as LD follow by 75 mg/day as MD for 5 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg
Description: The subjects administer Clopidogrel 600 as loading dose (LD) follow by 75 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Ticagrelor 90 mg/day as LD, follow by 90 mg/day as MD for 5 days).
Study: NCT04167293

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy
Description: Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks.

Intervention type: RADIATION
Group type: OTHER
Intervention: stereotactic body radiotherapy
Description: Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year. The first course of sintilimab will be given within 4-6 weeks after completion of SBRT.
Study: NCT04657926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APPA
Description: APPA, an oral combination of two isomers: 4-hydroxy-3-methoxyacetophenone (4H3MA) \& 2-hydroxy-4-methoxyacetophenone (2H4MA).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT03865186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation Program
Description: The program titled, Psychoeducation Program for Emotion Identification and Expression in Those Diagnosed with Schizophrenia was conducted with the patients in the intervention groups once a week for ten weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: no intervention
Study: NCT02865252

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MWM Treatment

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: MWM Sham
Study: NCT02275130

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxyapatite
Description: Surgical augmentation of the vocal cords with injection of calcium hydroxyapatite

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse Voice (Calcium Hydroxyapatite)
Study: NCT00937482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole-brain radiation therapy
Description: Undergo whole-brain radiotherapy
Study: NCT03607526

Intervention type: OTHER
Intervention: Barriers
Description: NGT sessions identifying barriers to vegetable intake.

Intervention type: OTHER
Intervention: Facilitators
Description: NGT sessions identifying facilitators to vegetable intake.
Study: NCT00296634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Description: Aluminum hydroxide adjuvant at 1200 mcg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Description: Aluminum hydroxide adjuvant at 1200 mcg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Description: Aluminum hydroxide adjuvant at 1200 mcg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Description: Aluminum hydroxide adjuvant at 1200 mcg/mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)
Description: Inactivated monovalent subvirion influenza H5N1 vaccine produced with and without Aluminum hydroxide adjuvant. All formulations of the H5N1 vaccine are supplied in a unit dose (0.5 mL) vial as a sterile solution for intramuscular injection. Vaccine with adjuvant is a turbid liquid whitish-grey in color. Vaccine without adjuvant is essentially clear and slightly opalescent in color.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)
Description: Inactivated monovalent subvirion influenza H5N1 vaccine produced with and without Aluminum hydroxide adjuvant. All formulations of the H5N1 vaccine are supplied in a unit dose (0.5 mL) vial as a sterile solution for intramuscular injection. Vaccine with adjuvant is a turbid liquid whitish-grey in color. Vaccine without adjuvant is essentially clear and slightly opalescent in color.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)
Description: Inactivated monovalent subvirion influenza H5N1 vaccine produced with and without Aluminum hydroxide adjuvant. All formulations of the H5N1 vaccine are supplied in a unit dose (0.5 mL) vial as a sterile solution for intramuscular injection. Vaccine with adjuvant is a turbid liquid whitish-grey in color. Vaccine without adjuvant is essentially clear and slightly opalescent in color.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)
Description: Inactivated monovalent subvirion influenza H5N1 vaccine produced with and without Aluminum hydroxide adjuvant. All formulations of the H5N1 vaccine are supplied in a unit dose (0.5 mL) vial as a sterile solution for intramuscular injection. Vaccine with adjuvant is a turbid liquid whitish-grey in color. Vaccine without adjuvant is essentially clear and slightly opalescent in color.
Study: NCT04221139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality games
Description: Participants will play the following four virtual reality games for 15 minutes each: Beat Saber, Holopoint, Hot Squat, and Relax Walk.
Study: NCT02086630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart to Heart
Study: NCT03166423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MU001 patches (Investigational)
Description: Patches containing snail slime, calendula extract and propolis extract

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional patches (Control)
Description: Patches containing conventional formulations in medical devices for ulcers (hydrocolloids, activated charcoal silver, alginate, carboxymethylcellulose or hydrogel).
Study: NCT02714517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hydrotherapy
Description: 30 minutes sessions of physiotherapy exercises in heated pool (32°C), three times per week for four weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: on land therapy
Description: 30 minutes sessions of physiotherapy exercises on land, three times per week for four weeks
Study: NCT04183075

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FontActiv Superprotein/Hypercaloric Fiber
Description: The product under study has a liquid presentation, in 200 ml bottles, ready to take

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrates and C Vitamin
Description: The control product will be prepared with equal presentation and taste as similar as possible tan study product
Study: NCT03456154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox Injectable Product
Description: 60u will be used at 3 sites of masseter muscle, on each side of the face

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal splint
Description: In this group patients will receive an occlusal splint which will be worn everyday for 6 months at night.
Study: NCT03850951

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lingual appliances
Description: Patients with moderate crowding will be treated without extraction using lingual appliances.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Labial appliances
Description: Patients with moderate crowding will be treated without extraction using labial appliances.
Study: NCT04433975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Pain Management (PPMI)
Description: The main theme of the treatment is to provide participants with new ways of thinking and coping skills related to managing pain and opioid use in order to increase the likelihood the participant may remain in buprenorphine treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: The EUC condition is designed to match the PPMI condition in terms of the non-specific aspects of receiving support for pain, substance use, and receiving monitoring of buprenorphine adherence.
Study: NCT05898191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vaginal laser treatment
Description: non-ablative vaginal laser application
Study: NCT04511767

Intervention type: OTHER
Intervention: Do not take any interventions
Description: Do not take any interventions

Intervention type: OTHER
Intervention: Do not take any interventions
Description: Do not take any interventions

Intervention type: OTHER
Intervention: Do not take any interventions
Description: Do not take any interventions
Study: NCT03415360

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cryoablation
Description: cryoablation of nerve responsible for phantom limb pain
Study: NCT01444001

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine
Description: 0.5 mL, intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine
Description: 0.5 mL, intramuscular
Study: NCT05409469

Intervention type: PROCEDURE
Intervention: surgery
Description: surgery on patients with aortic dissection

Intervention type: PROCEDURE
Intervention: surgery
Description: surgery on patients with aortic dissection
Study: NCT04015011

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LCD Intervention
Description: composed of approximately 1,080 kcal/day, which includes 3 New Direction Meal Replacements containing 200 kcal (27g protein, 12g carbhydrate, 2g fiber), 1 protein bar containing 160 kcal (5 g protein, 18g carbohydrate, 5g fiber, 2g sugar alcohol), and a 350-calorie controlled meal of protein and vegetables that the patient will make on his/ her own.
Study: NCT00703742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: A,1: Escitalopram, oral, 20 mg/day, 8 weeks
Study: NCT04739930

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow aspirate will be harvested and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to site of operation
Description: Autologous bone marrow aspirate will be processed and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to the site of operation in the treatment group

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control group incision
Description: 0.5cm sham incision over the iliac crest
Study: NCT00868829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Firebird2
Description: For the patient participated, only Firebird2 Stent will be implanted.
Study: NCT05408273

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples and Microvascular function assessment evaluated through laser-Doppler flowmetry by the LASER speckle contrast analysis (LASCA) device
Description: We enrolled 39 non-smokers, low CVR postmenopausal women, with less than 10 years of hypoestrogenism. Associations of 25(OH)D to adiposity, blood pressure, fasting aldosterone, insulin, glucose and lipid profile, HOMA-IR, parathormone and microvascular function, assessed by laser-Doppler flowmetry at cutaneous site, were investigated
Study: NCT02025803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-114/capecitabine
Description: Part 1 (dose-escalation phase):~Treatment cycles of TAS-114 and capecitabine orally BID for 14 days followed by 7 days rest until at least one of the discontinuation criteria are met TAS-114 dose starting at 20mg/m2/day with capecitabine dose of 760 mg/m2/day. TAS-114 doses will be escalated for each cohort up to 480mg/m2/day. If MTD is not reached by TAS-114 dose of 480mg/m2/day, the capecitabine dose will be escalated~Part 2 (expansion phase):~TAS-114 and capecitabine MTD established in Part 1 administered BID for 14 days followed by 7-day recovery period (21-day cycle).
Study: NCT01620450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic human insulin 30
Description: Single dose of each formulation administered subcutaneously (s.c., under the skin) on two separate visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic human insulin 30
Description: Single dose of each formulation administered subcutaneously (s.c., under the skin) on two separate visits
Study: NCT02846051

Intervention type: PROCEDURE
Group type: OTHER
Intervention: venous mapping
Description: clinical examination + doppler echo

Intervention type: PROCEDURE
Group type: OTHER
Intervention: venous mapping
Description: clinical examination + doppler echo
Study: NCT02030587

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Adrenalectomy
Study: NCT02039765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate
Study: NCT03263325

Intervention type: OTHER
Intervention: Discarded urine sample
Description: Collection of discarded urine during surgery and following surgery

Intervention type: OTHER
Intervention: Discarded urine sample
Description: Collection of discarded urine during surgery and following surgery
Study: NCT01960283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate (Novatrex ®) + anti-H1
Description: Methotrexate (Novatrex ®) tablets 2.5 mg methotrexate 0.2 mg/kg/week as a single dose, orally for 8 weeks.~After 8 weeks, if the treatment is still not efficient, the dose will be increased to 0.25 mg/kg/week and continued until W18.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and methotrexate will be added in this group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + anti-H1
Description: Placebo: 0.2 mg / kg / week as a single dose, orally for 8 weeks. After eight weeks, if the patient is still very embarrassed, the dose is increased to 0.25 mg / kg / week in a weekly dose.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and the placebo of methotrexate will be added in this group.
Study: NCT03634111

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: TAP block was performed under guidance with 0.25% ropivacaine 20 ml each side.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: Single dose was 1 mg. The locked time was 6 minutes. The limited dose was 40 mg/ 4 giờ.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Single dose was 1 mg. The locked time was 6 minutes. The limited dose was 40 mg/ 4 giờ.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 0.25% 20 ml each side

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 0.25% 20 ml each side
Study: NCT02100254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral intervention
Description: View personal narrative informational video

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral intervention
Description: View fact-based informational video
Study: NCT03961191

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA methylation
Description: DNA methylation for the cervical cytology

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA methylation
Description: DNA methylation for the cervical cytology

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA methylation
Description: DNA methylation for the cervical cytology

Intervention type: DIAGNOSTIC_TEST
Intervention: high-risk HPV
Description: High-risk HPV testing for the cervical cytology

Intervention type: DIAGNOSTIC_TEST
Intervention: high-risk HPV
Description: High-risk HPV testing for the cervical cytology

Intervention type: DIAGNOSTIC_TEST
Intervention: high-risk HPV
Description: High-risk HPV testing for the cervical cytology

Intervention type: DIAGNOSTIC_TEST
Intervention: TCT
Description: Thin prep liquid-based cytology test for the cervical cytology

Intervention type: DIAGNOSTIC_TEST
Intervention: TCT
Description: Thin prep liquid-based cytology test for the cervical cytology

Intervention type: DIAGNOSTIC_TEST
Intervention: TCT
Description: Thin prep liquid-based cytology test for the cervical cytology
Study: NCT04378101

Intervention type: OTHER
Intervention: Eating disorder diagnosis group
Description: This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.

Intervention type: OTHER
Intervention: Eating disorder diagnosis group
Description: This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.

Intervention type: OTHER
Intervention: Eating disorder diagnosis group
Description: This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.

Intervention type: OTHER
Intervention: Eating disorder diagnosis group
Description: This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.
Study: NCT02229981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC294640
Study: NCT02432937

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corever
Description: Corever

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corever
Description: Corever

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corever
Description: Corever
Study: NCT01696773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tangerine tomato juice
Description: Post-prandial feeding study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red tomato juice
Description: Post-prandial feeding study
Study: NCT01694433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriene
Description: 1g daily BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1g daily BID
Study: NCT03925272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of samples (blood, stool, etc.)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of samples (blood, stool, etc.)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of samples (blood, stool, etc.)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of samples (blood, stool, etc.)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of samples (blood, stool, etc.)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of samples (blood, stool, etc.)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of samples (blood, stool, etc.)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic determinants analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic determinants analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic determinants analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic determinants analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic determinants analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic determinants analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic determinants analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sample obtained after surgery performed in the context of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sample obtained after surgery performed in the context of care
Study: NCT04105686

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Infant Formula
Description: Ready to feed infant formula, feed ad libitum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: Ready to feed infant formula, feed ad libitum
Study: NCT03154255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean-Style Diet Educational Training
Description: The intervention consists in a standard diet according to routine clinical practice + a 30 minutes Mediterranean-Style Diet educational training with explanation of Mediterranean pyramid + gamification to Mediterranean diet inside the Hospital and at home throughout The Mediterranean Goose.
Study: NCT04094324

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: 4 questionnaires will be answered via iPads

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: 4 questionnaires will be answered via iPads
Study: NCT02776683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin